VectorBuilder and Sartorius Collaborate to Transform Biopharmaceutical Development

• VectorBuilder and Sartorius announced an expanded strategic cooperation agreement to enhance gene delivery and biopharmaceutical solutions.

• The collaboration focuses on innovations in cell and gene therapies, GMP-compliant production, and sustainability goals.

VectorBuilder, providing end-to-end gene delivery services, has joined forces with Sartorius, an international partner in life science research and the biopharmaceutical industry, to expand their longstanding partnership. The newly announced strategic agreement is set to accelerate innovations in gene vector and mRNA bioprocessing while advancing clinical applications in the biopharmaceutical sector.

The partnership covers several areas of collaboration, including the co-development of downstream processes for cell and gene therapies, optimisation of GMP-compliant production for mRNA, plasmids, and viral vectors, and support for sustainability initiatives. Additionally, both organisations will engage in talent exchange and training to foster innovation in the field of new modalities.

Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder, commented, “This agreement with Sartorius allows us to further expand our reach and impact, empowering researchers and pharmaceutical companies worldwide with advanced gene delivery solutions.”

Sartorius leaders echoed this sentiment, with Michaela Pischke, Head of the Business Area Separation Technologies, noting, “We look forward to leveraging the expertise of both companies to enable more innovations in downstream processing, further reducing time to market and ultimately saving more people’s lives.”